Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia
REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension
Sponsor: Renovis
This PHASE2 trial investigates Neuralgia and Peripheral Nervous System Disease and is currently ongoing. Renovis leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Aug 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Renovis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Boston, United States, Denver, United States, Houston, United States, Huntsville, United States, La Jolla, United States, Laguna Hills, United States, Madison, United States, Palm Beach Gardens, United States, Peoria, United States and 5 more location s